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Abstract
Background: The functional role of ELR-positive CXC chemokines during viral – induced demyelination was assessed.
Inoculation of the neuroattenuated JHM strain of mouse hepatitis virus (JHMV) into the CNS of susceptible mice results in an
acute encephalomyelitis that evolves into a chronic demyelinating disease, modeling white matter pathology observed in
the human demyelinating disease Multiple Sclerosis.
Methodology/Principal Findings: JHMV infection induced the rapid and sustained expression of transcripts specific for the
ELR (+) chemokine ligands CXCL1 and CXCL2, as well as their binding receptor CXCR2, which was enriched within the spinal
cord during chronic infection. Inhibiting CXCR2 signaling with neutralizing antiserum significantly (p,0.03) delayed clinical
recovery. Moreover, CXCR2 neutralization was associated with an increase in the severity of demyelination that was
independent of viral recrudescence or modulation of neuroinflammation. Rather, blocking CXCR2 was associated with
increased numbers of apoptotic cells primarily within white matter tracts, suggesting that oligodendrocytes were affected.
JHMV infection of enriched oligodendrocyte progenitor cell (OPC) cultures revealed that apoptosis was associated with
elevated expression of cleaved caspase 3 and muted Bcl-2 expression. Inclusion of CXCL1 within JHMV infected cultures
restricted caspase 3 cleavage and increased Bcl-2 expression that was associated with a significant (p,0.001) decrease in
apoptosis. CXCR2 deficient oligodendrocytes were refractory to CXCL1 mediated protection from JHMV – induced
apoptosis, readily activating caspase 3 and down regulating Bcl-2.
Conclusion/Significance: These findings highlight a previously unappreciated role for CXCR2 signaling in protecting
oligodendrocyte lineage cells from apoptosis during inflammatory demyelination initiated by viral infection of the CNS.
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Introduction
How chemokine receptor signaling contributes to chronic
neurologic diseases has largely been considered within the context
of targeted leukocyte recruitment into the CNS [1]. However,
numerous resident cell types of the CNS express chemokine
receptors under non-inflammatory and inflammatory conditions
(reviewed in [2,3]), indicating that these cells are capable of
responding to specific chemokine ligands. Thus, chemokine
signaling may participate in either repair and/or exacerbation of
pathology following insult, injury, or infection of the CNS [4–6].
CXCR2, the receptor for the murine ELR+ CXC chemokine
ligands CXCL1,22,23, 25, 26 and 27, has been detected either
in vitro or in vivo upon resident cells of the CNS, including
oligodendrocyte precursor cells (OPC) [7–12]. Expression of
CXCR2 on OPC is critical in the positional migration of these
cells during development and axon myelination [12–14], and
CXCR2 has been suggested to be important in regulating
remyelination following experimental demyelination [5,6,15].
Additionally, in active MS plaque lesions CXCR2 has been found
upon proliferating oligodendrocytes and reactive astrocytes, while
its ligand CXCL1 has been associated with activated astrocytes
[10,11].
Following experimental infection with the neurotropic viruses
including the JHM strain of mouse hepatitis virus (JHMV) or
Theiler’s murine encephalomyelitis virus (TMEV), both CXCL1
and CXCL2 are up regulated within the CNS. Moreover, in vitro
experiments revealed that JHMV - and TMEV - infected
astrocytes readily express CXCL1 and CXCL2, suggesting that
astrocytes are the primary source for these chemokines in vivo
[16,17]. The presence of CXCR2 and/or signaling ligands during
numerous CNS inflammatory pathologies implies a potential role
for CXCR2 signaling in protection or disease progression, yet a
functional role for ELR+ chemokines and/or CXCR2 in a chronic
virus - induced neuroinflammatory disease remains incompletely
understood. In particular, the relative activities of the ELR+
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11340chemokines towards leukocytes and resident neuroepithelial cells
have not been differentiated.
The present study was undertaken to characterize, for the first
time, the functional role of ELR+ chemokines during chronic viral
infection of the CNS. Inoculation with JHMV into the CNS of
susceptible strains of mice results in an acute encephalomyelitis
characterized by wide spread infection of astrocytes, microglia,
and oligodendrocytes and relative sparing of neurons [18].
Although a robust cell-mediated immune response occurs during
acute disease [19,20], sterilizing immunity is not achieved, and
JHMV persists primarily within oligodendrocytes [21]. Histolog-
ical features associated with viral persistence include the
development of an immune-mediated demyelinating disease
analogous to the human demyelinating disease multiple sclerosis
(MS), with both T cells and macrophages important in amplifying
disease severity by contributing to myelin damage [22,23]. Using
JHMV infection as a model of immune-mediated demyelination,
we demonstrate a previously unappreciated role for ELR-positive
chemokines in protecting cells of the oligodendrocyte lineage from
apoptosis during viral – induced demyelination.
Results
CXCR2 and its ligands CXCL1 and CXCL2 are upregulated
during viral – induced demyelination
To investigate the role of CXCR2 signaling during chronic –
viral encephalomyelitis, C57BL/6 mice were intracerebrally (i.c.)
inoculated with JHMV, and the mRNA expression pattern of
CXCR2, as well as its associated ELR+ chemokines CXCL1,
CXCL2, and CXCL5, was assessed within the spinal cord, the
primary site of demyelination during chronic disease. Within the
spinal cord, JHMV viral loads peaked at 1 week post-infection (p.i)
before declining to below the level of detection (100 pfu/g) by day
18 p.i. (Figure 1A). Significantly (p#0.01) elevated mRNA
Figure 1. CXCR2 and ELR+ chemokines are upregulated within the spinal cord during chronic JHMV infection. C57BL/6 mice were i.c.
infected with 500 pfu JHMV and spinal cords removed at defined times p.i. to assess viral burden (A) and transcripts specific for CXCR2, CXCL1,
CXCL2, and CXCL5 using semi-quantitative real time PCR (B). For PCR results, data represents the fold induction relative to sham infected mice (n=3–
5, *p,0.05, **p,0.01, ***p,0.001). Representative immunofluorescence of the spinal cord white matter at 15 days p.i reveals CXCL1 expression
within reactive hypertrophic GFAP+ astrocytes (C).
doi:10.1371/journal.pone.0011340.g001
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throughout infection compared to sham-infected control mice,
and expression was independent of viral load (Figure 1B).
Immunostaining for CXCL1 revealed that GFAP+ astrocytes are
the primary cellular source of CXCL1 within the spinal cord
(Figure 1C). The prolonged and elevated expression of the
CXCR2 ligands CXCL1 and CXCL2 mRNA throughout the
course of JHMV infection within the spinal cord, coupled with the
localized CXCL1 expression within spinal cord white matter,
implicate a potential role for CXCR2 signaling in host defense
during chronic JHMV infection.
Blocking CXCR2 increases the severity of clinical disease
To assess a functional role for signaling by ELR+ chemokines
during chronic viral – induced demyelination, JHMV infected
C57BL/6 mice were treated with CXCR2 neutralizing antiserum
or control serum (NRS) from days 12–20 p.i, after which mice
were allowed to recover until day 35 p.i. Administration of anti-
CXCR2 treatment resulted in sustained clinical disease compared
to mice treated with control antiserum (Figure 2A). CXCR2
neutralization did not influence JHMV viral loads within either
the brain or spinal cord during chronic infection, as determined by
measuring viral titers by plaque assay at defined times post-
treatment (Figure 2B). In addition, immunophenotyping the
cellular infiltrate by flow cytometry in mice treated with anti-
CXCR2 revealed that the frequency and total numbers of CD4+
T lymphocytes, CD8+ T lymphocytes, infiltrating macrophages
(CD45
high/F480+), and neutrophils (Ly6G+ CD11b+) were similar
when compared to mice treated with control serum (Figure 3
and Table S1). Correspondingly, chemokine mRNA expression
within the CNS was not affected (Figure S1). Moreover, blocking
CXCR2 did not affect total numbers of virus-specific CD4+ or
CD8+ T cells, as determined by intracellular IFN-c staining to
defined immunodominant peptides, when compared to mice
treated with control serum (Figure 4). Therefore, the increase in
clinical severity in mice treated with anti-CXCR2 was neither the
result of viral recrudescence, nor alteration in the composition or
frequency of infiltrating immune cells.
Blocking CXCR2 increases the severity of demyelination
associated apoptosis in white matter tracts
Quantification of demyelination at day 35 p.i. across the length
of the spinal cord revealed a significant (p#0.007) increase in the
severity of demyelination within mice receiving CXCR2 antiserum
compared to those receiving control serum (Figure 5A and B).
One potential explanation for the worsened demyelination would
be that oligodendrocytes were undergoing programmed cell death.
Therefore we next determined whether mice treated with anti-
CXCR2 displayed an increase in apoptotic cells within the CNS
compared to control-treated mice. CXCR2 neutralization signif-
icantly (p#0.001) enhanced the number of TUNEL-reactive
nuclei at days 15 and 17 p.i. within the white matter parenchyma
of treated mice compared mice treated with control serum
(Figure 6A). Regions of TUNEL-positive cells were restricted to
white matter tracts, and both the area and density of TUNEL
reactivity was increased within anti-CXCR2 treated mice. Greater
than 90% of the TUNEL reactive cells also co-localized with
cleaved caspase 3, indicating that the cells within the white matter
of mice receiving CXCR2 antiserum were undergoing an
apoptotic and not necrotic death (Figure 6B). Immunofluores-
cence staining for the oligodendrocyte precursor marker Olig 2
(Figure 6C) and the oligodendrocyte marker CC1 (Figure 6D),
revealed apoptotic oligodendrocyte lineage cells within the white
matter of anti-CXCR2 treated mice. The increase in apoptosis did
not appear to be a direct causal result of viral persistence within an
individual cell, as similar frequencies of apoptotic cells containing
JHMV nucleocapsid antigen were observed in both experimental
groups of mice (data not shown). These data collectively indicate
that CXCR2 signaling during chronic JHMV infection enhances
protection of cells of the oligodendrocyte lineage from apoptosis.
CXCR2 signaling reduces JHMV – induced
oligodendrocyte apoptosis in vitro
Previous reports have indicated that JHMV directly induces
apoptosis of infected oligodendrocytes in vitro [24–27]. Therefore
to determine whether CXCR2 signaling can protect against
JHMV – mediated apoptosis of oligodendrocytes, an in vitro culture
system using enriched glial cultures derived from differentiated
neural precursor cells (NPCs) was employed. Differentiation
resulted in .80% of cells expressing the oligodendrocyte marker
GalC; the remaining cells expressed either the astrocyte marker
GFAP or neuron maker MAP2 (Figure S2A). Differentiated
oligodendrocytes also constitutively expressed CXCR2 (Figure
S2B). Infection of oligodendrocyte – enriched cultures with JHMV
(MOI=1.0) increased TUNEL staining, suggesting that oligoden-
Figure 2. CXCR2 neutralization mutes spontaneous recovery
from JHMV induced demyelination. C57BL/6 mice were i.c.
infected with 500 pfu JHMV and treated with neutralizing CXCR2
antiserum or control normal rabbit serum (NRS) i.p. from day 12 to 20,
indicated by the shaded box. Treated mice were allowed to recover for
a further two weeks and clinical severity was assessed (A). In addition,
brains and spinal cords from treated mice were removed at the
beginning, middle, and end of treatment to assess JHMV viral burden
(B). For panel A data is a summation of four independent experiments
(anti-CXCR2 n=32; NRS n=31). For panel B data is a summation of two
independent experiments.
doi:10.1371/journal.pone.0011340.g002
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(Figure 7A & B). Indeed, Western blotting confirmed the
induction of apoptosis. Following JHMV infection, we observed
the cleavage of procaspase 3 (35 kDa) into its active form (17 kDa),
in combination with cleavage of the caspase 3 target PARP, and
muted expression of Bcl2, a member of the anti-apoptotic Bcl-x
family of proteins, confirming previous reports [24–27] that in vitro
JHMV triggers apoptosis within infected oligodendrocyte cultures
(Figure 8B–D). We next assessed whether or not apoptosis was
limited to JHMV infected oligodendrocytes or was more
widespread amongst uninfected oligodendrocytes in the culture.
Immunostaining for viral nucleocapsid in conjunction with
TUNEL revealed that slightly more than half of the TUNEL
reactive cells were positive for viral antigen (Figure 7C & D).
Therefore, although there was a modest but significant (p#0.03)
enrichment of viral antigen amongst the apoptotic cells, a large
proportion of apoptotic cells were unreactive for viral antigen,
suggesting that additional mechanisms for apoptosis exist that are
not dependent upon viral replication within the target cell
(Figure 7D). When recombinant CXCL1 was included within
JHMV infected cultures, we observed a significant (p#0.001) dose
– dependent reduction in the induction of apoptosis as determined
by TUNEL (Figure 7A). Moreover, we were unable to detect
either the activation of caspase 3 or the cleavage of PARP, while
Bcl-2 was restored to control levels, suggesting that CXCL1 is
protective with regards to JHMV – induced apoptosis (Figure 8B–
D). To confirm the importance of CXCR2 – mediated signaling in
protection from JHMV – induced apoptosis, oligodendrocyte
enriched cultures were derived from CXCR2
2/2 mice. JHMV
infection of CXCR2
2/2 cultures resulted in a similar frequency of
TUNEL reactive cells as compared to infected wildtype cells, yet
CXCL1 did not protect oligodendrocyte cultures from undergoing
apoptosis (Figure 8A), and this correlated with the presence of
activated caspase 3, cleaved PARP, and no restoration of Bcl-2
Figure 3. CXCR2 neutralization does not alter neuroinflammation during chronic JHMV infection. C57BL/6 mice were i.c. infected with
500 pfu JHMV and treated with neutralizing CXCR2 antiserum or control normal rabbit serum (NRS) i.p. from day 12 to 20. Brains (A–D) and/or spinal
cords (E) were removed from perfused mice at defined times p.i. and were assessed for CD4+ (A), CD8+ T lymphocyte (B), macrophage (C), and
neutrophil (D&E ) accumulation within the CNS. Data in panels A–C are representative of four independent experiments, and data in panels D&Eare
representative of two independent experiments.
doi:10.1371/journal.pone.0011340.g003
CXCR2 Protects Oligodendroglia
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11340expression (Figure 8B–D). Collectively these data demonstrate
the potent role for CXCL1 and CXCR2 in preventing
oligodendrocyte apoptosis in vitro.
Discussion
This study has provided previously unappreciated evidence that
CXCR2 signaling protects cells of the oligodendrocyte lineage
from apoptosis in mice persistently infected with a demyelinating
neurotropic virus. Administration of a blocking antibody specific
for CXCR2 resulted in increased clinical disease severity
associated with enhanced demyelination. The increase in demy-
elination was not the result of increased viral load or neuroin-
flammation, indicating alternative mechanisms were responsible
for white matter damage. Indeed, anti-CXCR2 treatment
increased the overall numbers of apoptotic cells concentrated
within demyelinated white matter. In vitro studies confirmed our
observations in animal studies and emphasized the importance of
CXCR2 signaling in protecting oligodendrocyte – enriched
cultures from apoptosis through a mechanism associated with
controlling Bcl2 expression. Therefore, these findings highlight the
importance of CXCR2 signaling in preferential protection of
white matter from demyelination in a model of viral persistence
associated with on-going neuroinflammation.
In many diverse instances of CNS infection, inflammation, and
injury, including MS, EAE, and Theiler’s murine encephalitis virus
(TMEV), CXCR2 and/or its ligands are upregulated [10,11,17,28–
32]. During JHMV infection, the CXCR2 ligands CXCL1 and
CXCL2 are significantly upregulated and persist within the spinal
cord throughout chronic infection, even in the absence of infectious
virus. Additionally, we have observed hypertrophic astrocyte
derived CXCL1, consistent with previous observations within
actively demyelinating MS and EAE plaques [10,11,32].
How CXCR2 signaling participates in initiating neuroinflam-
matory demyelinating diseases has recently been examined. Using
EAE as a model of autoimmune demyelination, Segal and
colleagues [28] demonstrated that early expression of CXCR2
ligands is critical in both disease initiation and relapse by
promoting the accumulation of CXCR2-expressing neutrophils
to the CNS that regulate the permeability of the BBB. Similarly,
we have recently shown that during acute JHMV-induced
encephalomyelitis CXCR2 ligands are important in host defense
by attracting neutrophils into the CNS, facilitating the subsequent
loss of BBB integrity that permits the entry of virus-specific T cells
[1]. Also, during cuprizone – induced demyelination we [15]
reported that neutrophil effector function, mediated through
CXCR2, is necessary for the initiation of demyelination. However,
unlike these previous reports that demonstrated the CXCR2
signaling axis to be an important determinant of immune cell
infiltration or function within the CNS, blocking CXCR2
signaling during chronic JHMV-induced disease did not influence
the infiltration of the traditional mediators of JHMV – induced
demyelination, namely T – lymphocytes and macrophages
[33,34]. Moreover, although neutrophils comprise a rare popula-
tion of inflammatory cells, near the limits of detection within the
CNS during chronic JHMV infection, their numbers or frequen-
cies were not affected following CXCR2 neutralization.
Our findings reveal that CXCR2 signaling is instead important
in limiting the severity of demyelination in JHMV – infected mice.
Neutralization of CXCR2 significantly delayed clinical recovery
and similarly increased the overall extent of demyelination within
the spinal cord, and this was associated with a significant increase
Figure 4. CXCR2 neutralization does not diminish virus – specific T cell infiltration during chronic JHMV infection. C57BL/6 mice were
i.c. infected with 500 pfu JHMV and treated with neutralizing CXCR2 antiserum or control normal rabbit serum (NRS) i.p. from day 12 to 18. Brains (A &
B) and spinal cords (C & D) were removed at defined times p.i. and isolated cells were stimulated ex vivo for six hours with 5 mM of the
immunodominant CD4+ epitope M133–147 (A & C)o r5mM of the immunodominant CD8+ epitope S510–518 (B & D) before intracellular IFNc staining
was assessed. Data is representative of two independent experiments.
doi:10.1371/journal.pone.0011340.g004
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tracts. Apoptotic cells have been previously observed within areas
of demyelination during chronic JHMV infection [35,36],
however apoptosis has not been thought to play a major role in
pathogenesis [36]. Recent evidence has demonstrated that in vitro
JHMV induces caspase – dependent apoptosis within oligoden-
drocytes through Bax translocation into the mitochondria
[24,25,27]. During chronic JHMV infection, oligodendrocytes
represent an important viral reservoir [21,37,38]; therefore it is
likely that some mechanisms exist in vivo to protect oligodendro-
cytes from JHMV – induced apoptosis. In addition to JHMV,
oligodendrocytes are also sensitive to FasL [39], TNFa[40,41],
and IFNc [42,43] – induced apoptosis, all of which are detectable
during chronic JHMV infection [44,45]. Oligodendrocyte apop-
tosis, through FAS and TNFR1 signaling, has been suggested to be
important for the induction of demyelination during EAE, as the
absence of one or both of these apoptosis signaling receptors upon
oligodendrocytes reduces both the severity and onset of clinical
symptoms [46]. Furthermore, Gold and colleagues demonstrated
that when oligodendrocyte apoptosis is enhanced, both the
disability and clinical onset of EAE are exacerbated [47]. Studies
in MS postmortem tissue have also indicated that oligodendrocyte
apoptosis may be an important pathogenic step in a subset of
lesions [48]. During coronavirus infection, apoptosis is not
restricted to oligodendrocyte lineage cells; microglia and astrocytes
have also been reported to undergo apoptosis within demyelinated
lesions [35]. Indeed we also observed microglial and astrocytic
apoptosis (data not shown), however there is little evidence
directly linking either microglial or astrocyte apoptosis to
demyelination in vivo. Therefore, since mice receiving CXCR2
antiserum experienced enhanced clinical severity and demyelin-
ation, we focused upon whether CXCR2 signaling was capable of
enhancing oligodendrocyte survival in vitro.
To determine whether or not CXCR2 signaling was capable of
preventing oligodendrocyte apoptosis, JHMV infected cultures
were treated with the CXCR2 ligand CXCL1. JHMV infected
cultures readily initiated apoptosis, activated caspase 3 and
downregulated Bcl-2. Slightly more than half of all apoptotic
oligodendrocytes were reactive for viral nucleocapsid, suggesting
additional complex apoptotic mechanisms in addition to JHMV
replication, perhaps through glutamate excitotoxicity [49], as viral
infections or cytokine stimulation of astrocytes abrogates in vitro
glutamate uptake [50–52]. JHMV can also induce apoptosis
without viral replication through spike glycoprotein and FAS
interactions [24,27], therefore JHMV may also be activating
apoptosis in the absence of viral replication. Nevertheless, CXCL1
treatment protected oligodendrocyte cultures from JHMV –
induced apoptosis, and this was associated with reduced caspase
Figure 5. CXCR2 neutralization increases white matter demyelination. C57BL/6 mice were i.c. infected with 500 pfu JHMV and treated with
neutralizing CXCR2 antiserum or control normal rabbit serum (NRS) i.p. from day 12 to 20. Spinal cords were removed at day 35 p.i. and coronal
sections along the length of the spinal cord were stained with luxol fast blue to assess myelin integrity (A). Quantification of the total area of
demyelination along the entire length of the spinal cord (B) revealed a significant increase in the percent demyelinated area of mice treated with
CXCR2 antiserum (solid outline indicates total white matter, dashed outline indicates area of demyelinated white matter). Data is a summation of four
independent experiments (anti-CXCR2 n=19, NRS n=23).
doi:10.1371/journal.pone.0011340.g005
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deficient cultures infected with JHMV were completely insensitive
to CXCL1 – mediated protection, indicating that the protection
observed following CXCL1 treatment is mediated through
CXCR2. Bcl-2, a member of the large BH family of anti – and
pro – apoptotic factors, antagonizes Bax/Bak mediated mito-
chondrial membrane permeabilization, preventing cytochrome C
release and the subsequent induction of apoptosis [53,54]. Within
JHMV infected oligodendrocytes, forced overexpression of Bcl-2
or Bcl-xl, a pro – survival Bcl-2 family member, prevented or
muted JHMV – mediated apoptosis [25,26], presumably by
interfering with Bax [25,53,54]. Additionally, within MS lesions,
oligodendrocyte Bcl-2 expression is highly correlative with the
presence of remyelination [55].
CXCL1 plays an important role in arresting the migration of
oligodendrocyte precursors during development [12], however,
whether CXCL1 performs a similar role within the adult white
matter remains uncertain. It has been suggested that the CXCL1
associated with MS lesions [10,11] may prevent oligodendrocyte
precursor cell migration into regions of demyelination and thus
prevent subsequent remyelination and recovery [56]. We have not
observed any aberrant oligodendrocyte trafficking or localization
within mice treated with neutralizing CXCR2 antiserum (data
not shown). In other complementary models of demyelination
and recovery the role of CXCR2 remains enigmatic. Our findings
are in marked contrast with a recent report that CXCR2 negatively
influences remyelination and recovery following autoimmune
demyelination. Using a chemical inhibitor of CXCR2, Miller
and colleagues [5] observed that mice receiving a CXCR2
antagonist experienced reduced clinical severity and improved
remyelination either during EAE or following lysolecithin micro-
injection-induced demyelination. The authors postulated that the
enhanced recovery observed was due to the removal of a
migrational blockade and enhanced differentiation of oligoden-
drocyte precursor cells, however, whether CXCR2 directly
inhibited oligodendrocyte remyelination was ambiguous since
CXCR2 antagonism also was associated with reduced macro-
phage/microglia infiltration [5]. During spinal cord development,
we found that CXCR2 - deficient mice experienced abnormal
myelination as their oligodendrocyte progenitors were unable to
properly arrest and spatially localize within the presumptive white
matter [12]. Additionally, OPCs in P7 CXCR2
2/2 mice exhibited
reduced proliferation and lower levels of programmed cell death
[12]. Notably, CXCR2 knockout mice (C57Bl/6) also were
resistant to cuprizone – mediated demyelination due to, in part,
deficient neutrophil effector function [15]. Different from these
results, Raine and colleagues [6] reported a protective role for
CXCR2 signaling during demyelination. Transgenic overexpres-
sion of CXCL1 within astrocytes induced at disease onset during
EAE led to a reduction in late stage clinical severity and
demyelination, while enhancing remyelination [6]. We observed
that during chronic viral induced demyelination, CXCR2
neutralization delays clinical recovery, enhances demyelination,
and increases apoptosis within white matter without influencing
viral load or neuroinflammation. Our in vitro studies demonstrated
that CXCR2 specifically protects oligodendrocytes from JHMV –
induced apoptosis. In various models of CNS demyelination and
inflammation, CXCR2 has been shown to have enigmatic roles
during recovery and repair. Therefore, it is plausible that the pro-
apoptotic and pro-survival actions of CXCR2 towards oligoden-
drocytes will prove to be context-dependent. Adding complexity,
clarifying the diverse roles of CXCR2 in neuroinflammation will
need to incorporate the extent to which neutrophilic inflammation
[1,15,28] is relevant for the process under study.
Figure 6. CXCR2 neutralization increases oligodendrocyte lineage cell apoptosis in the spinal cord. C57BL/6 mice were i.c. infected with
500 PFU JMHV and were treated with CXCR2 neutralizing antiserum or control normal rabbit serum (NRS) every other day beginning at day 12 p.i. Mice
were sacrificed at day 15 and 17 p.i. and spinal cords were removed and processed for TUNEL labeling. (A) Quantification of the number of white matter
TUNEL-positive nuclei revealed an approximate 3 to 4 fold increase in the number of apoptotic cells in anti-CXCR2 treated mice (*** p,0.001) compared
toNRS-treatedmiceatdays15and17p.i.(B)Co-immunofluorescenceofTUNELwithcleavedcaspase3confirmedthat TUNELreactivecellswereindeed
apoptotic. Immunophenotyping the TUNEL-positive cells revealed apoptotic (C)C C 1
+ oligodendrocytes and (D) Olig2
+ oligodendrocyte precursor cells.
Data presented is representative of two independent experiments. Bars: (B)2 0mm; (C&D )5 0mm; (C&D ) inset 5 mm.
doi:10.1371/journal.pone.0011340.g006
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development. Therefore it is plausible that CXCR2 on oligoden-
drocytes and astrocytic CXCL1 near MS lesions [10,11] may
function to promote oligodendrocyte survival. Taken together, we
propose a potentially novel role for the chemokine receptor
CXCR2 during chronic inflammatory conditions: not as a cellular
chemoattractant that influences immune cell infiltration, but as a
potent protective stimulus, preventing apoptosis.
Materials and Methods
Virus and mice
Age-matched 5–6 week old C57BL/6 mice (C57BL/6, H-2
b,
National Cancer Institute, Frederick, MD) were infected intracra-
nially (i.c.) with 500 plaque forming units (PFU) of MHV strain
J2.2v-1 (JHMV) in 30 ml of sterile HBSS. Control (sham) animals
were injected with 30 ml of sterile saline alone. Mice were sacrificed
at various days post - infection (p.i.) and brains/spinal cords
removed and processed for analysis. For analysis of viral titers, one-
half of each brain or the entire spinal cord was homogenized and
used for standard plaque assay on the DBT mouse astocytoma cell
line [57] at the indicated days p.i. All experiments were approved
by the University of California, Irvine Institutional Animal Care
and Use Committee protocol # 1998–2022.
Antibody production and administration
Rabbit polyclonal antiserum was generated to a 17-amino acid
portion of the amino-terminus ligand binding domain of CXCR2
(MGEFKVDKFNIEDFFSG) [58]. The CXCR2 antiserum specif-
ically blocks CXCR2 dependent infiltration of neutrophils into the
Figure 7. The CXCR2 ligand CXCL1 protects oligodendrocytes from JHMV – mediated apoptosis in vitro. Differentiated oligodendrocyte
enriched cultures were infected with JHMV (moi 1.0), treated with varying concentrations of recombinant mouse CXCL1, and assessed for apoptosis via
TUNEL 24 hours p.i. (A) CXCL1 protected oligodendrocytes from JHMV – mediated apoptosis in a dose dependent manner (*** p,0.001, relative to
JHMV only; * p,0.05 relative to Mediaonly).(B) A representative imageof an apoptotic oligodendrocyte following JHMV infection. (C) Immuno-staining
for JHMV nucleocapsid (green) in addition to TUNEL (red) revealed both apoptotic JHMV infected anduninfected oligodendrocytes; note the absence of
apoptosis within JHMV infected oligodendrocytes treated with CXCL1 at 10 ng/ml. (D) Quantification of the frequency of JHMV infected cells amongst
TUNEL+ cells revealed that slightly greater than half of the apoptotic cells (p#0.03) were reactive for JHMV nucleocapsid. Data in panels A&Dis a
summation of three independent experiments. Data in panels B&Cis representative of three independent experiments. Bars: (B)6 0mm; (C)3 0mm.
doi:10.1371/journal.pone.0011340.g007
CXCR2 Protects Oligodendroglia
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11340peritoneum of mice following thioglycollate irritation [59] and does
not bind rabbit complement and deplete neutrophils in vitro [1,28].
For in vivo neutralization during JHMV infection, 0.5 ml of anti-
CXCR2 or control normal rabbit serum (NRS) was administered
intraperitoneally (i.p.) on days 12, 14, 16, 18, and 20 p.i.
Semi-Quantitative Real Time PCR
Total cDNA from the spinal cords of sham and JHMV infected
mice at days 1, 3, 7, 12, 15, 18, and 21 p.i. was generated as
previously described [45]. Real-time Taqman analysis for HPRT,
CXCR2, CXCL1, CXCL2, and CXCL5 was performed using a
BioRad (Hercules, Ca) iCycler with previously described primers
and probes [60,61]. CXCR2 and CXCL1, -2, &-5 expression was
normalized to HPRT. Probes were purchased from Integrated
DNA Technologies (Coralville, IA), and primers were purchased
from Invitrogen (Carlsbad, CA). iQ Supermix (BioRad) was used
for all reactions. Assay conditions were as follows: a 4.5 min - at
95uC, and 45 cycles of 30 sec at 95uC and 1 min at 58uC. Data
were analyzed with BioRad iCycler iQ5 and quantified with the
Relative Expression Software Tool [62].
Ribonuclease Protection Assay
Chemokine mRNA transcripts were analyzed as previously
described [33]. Briefly, total RNA isolated from the brains of anti-
CXCR2 and NRS treated mice were analyzed with the mCK5c
probe set (BD Biosciences) according to manufacturer instructions.
For quantification of signal intensity, individual chemokine band
intensity was normalized to L32 control using Image J (NIH).
Cellular Infiltration Analysis
Flow Cytometry was performed as previously described
[33,63,64]. Isolated cells were Fc blocked with anti-CD16/32
1:200 (BD Biosciences, CA) and immunophenotyed with fluores-
cent antibodies (BD Biosciences) specific for the following cell
surface markers: CD4 (L3T4), CD8b (53-5.8), CD8a (53-6.7),
Ly6G (1A8), CD11b (M1/70), CD45 (30-F11, E Biosciences), and
F4/80 (CI:A3-1, Ab Direct, NC. Appropriate isotype antibodies
were used for each antibody. For determination of viral specificity,
isolated CNS cells were stimulated ex vivo for 6 h with 5 mM of the
immunodominant CD4 epitope M133–147 [65] or the immunodo-
minant CD8 epitope S510–518 [66] and GolgiStop (Cytofix/
Cytoperm kit, BD Biosciences), and the production of IFNc was
determined by intracellular staining. Cells were Fc blocked with
CD16/32 and stained with FITC – or APC – conjugated CD4,
CD8a, or CD8b antibodies (BD Biosciences) before being fixed
and permeablized with the Cytofix/Cytoperm kit and stained with
PE – conjugated IFNc (XMG1.2, BD Biosciences). Appropriate
isotype antibodies were used for each antibody. Cells were run on
a FACStar flow cytometer (BD Biosciences) and analyzed with
FlowJo software (TreeStar, OR).
Figure 8. CXCR2 deficient oligodendrocytes are insensitive to CXCL1 – mediated protection from apoptotis. Differentiated CXCR2+/+
and CXCR22/2 oligodendrocyte enriched cultures were infected with JHMV (moi 1.0) and treated with recombinant mouse CXCL1 at 10 ng/ml. (A)
While CXCL1 protected CXCR2+/+ oligodendrocytes from JHMV-mediated apoptosis, CXCR22/2 oligodendrocytes were not protected (*** p#0.001,
relative to Media). Protein lysates were collected from JHMV infected CXCR2 +/+ and CXCR22/2 cultures and cleaved caspase 3, the caspase target
PARP, and Bcl-2 expression were assessed (B). Densitometric quantification of the cleaved caspase 3 and Bcl-2 blots is presented panels C and D.
Data in panels A–D is representative of three independent experiments.
doi:10.1371/journal.pone.0011340.g008
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Clinical severity was assessed using a previously described 4
point scoring scale [33]. Spinal cords from 4% paraformaldehyde
perfused mice were removed and fixed overnight in 4%
paraformaldehyde at 4uC. Spinal cords were separated into
twelve 1.5 mm coronal sections, cryoprotected in 20% Sucrose
and embedded in OCT. Seven micron thick coronal sections
were cut along the length of the spinal cord and stained with luxol
fast blue. Areas of total white matter and demyelinated white
matter were determined with Image J (NIH). Data is expressed as
the percent of total demyelination along the entire length of the
spinal cord.
Immunofluorescence and TUNEL
Tissues were fixed and processed as above. For immunofluo-
rescence, slides were fixed in 4% paraformaldehyde and blocked
with 10% Normal Donkey Serum and 0.3% Triton-X 100.
Primary antibodies were added serially overnight at 4uC: chicken
anti – mouse GFAP 1:1000 (Abcam, MA), goat anti – mouse
CXCL1 (2 ug/ml, R&D Systems, MN), rabbit anti – cleaved
caspase 3 rabbit 1:400 (Cell Signaling, MA), mouse anti – mouse
APC (CC1) 1:20 (Calbiochem, CA), rabbit anti – mouse Olig2
1:500 (Abcam). Appropriate fluorescent conjugated donkey
secondary antibodies were used for visualization (Jackson Im-
muno, PA). For analysis of in situ apoptosis a Fluorescein or TMR-
red TUNEL kit was used (Roche) according to the manufacturer’s
instructions. For co-immunofluorescence to identify activated
caspase 3 – positive and TUNEL – positive cells, slides were first
TUNEL stained according to manufacturer’s instructions and
subsequently blocked and assayed with the activated caspase 3
antibody as above. Appropriate TRITC secondary antibodies
were then used for visualization (Jackson Immuno). Quantification
of TUNEL and areas of white matter was assessed with Image J.
Isolation of primary oligodendrocyte – enriched cultures
Striatum from postnatal day 1 CXCR2+/+ and CXCR22/2
mice were dissected, triturated, and cultured as previously
described [67,68]. Briefly, dissected striata were razor minced
and triturated in prewarmed 0.05% trypsin (Invitrogen) for
10 min. Trypsin digestion was halted with 10 ml of 1X anti-
trypsin (Invitrogen). Cells were resuspended in DMEM:F12
(Invitrogen) supplemented with 1X B27, Insulin – Transferrin –
Selenium – X (Invitrogen), T3, and 20 ng/ml human recombinant
EGF (Sigma) and cultured in low adherent flasks for 5 days.
Neurospheres were subsequently collected and transferred into
MatriGel coated flasks (BD Biosciences). One day after transfer,
EGF was omitted from the media to induce differentiation. Two
days after EGF starvation, cells were trypsinized and replated onto
MatriGel coated 6 well plates at 1e6 cells/well. Cultures were
incubated a further 1–2 days before being assayed. To assess
culture purity and CXCR2 expression, 4 day differentiated
cultures were washed in cold HBSS and fixed in 4% paraformal-
dehyde and blocked with 10% goat serum. Primary antibodies
were added serially overnight: mouse anti – mouse Gal/C mouse
1:500 (Chemicon, CA), mouse – anti mouse Map2 1:750 (Sigma,
MO), rabbit anti – bovine GFAP rabbit 1:500 (Invitrogen), or
rabbit anti – mouse CXCR2 antiserum 1:500. Appropriate
conjugated goat secondary antibodies were used for visualization
(Invitrogen). To assess apoptosis, cultures were similarly washed
and fixed in 4% paraformaldehyde before being subjected to a
TMR-red TUNEL kit (Roche) according to manufacturer
instructions. Viral infected cells were detected within TUNEL
stained cultures using a mouse monoclonal antibody anti-JHMV
(J.3.3, 1:20) directed against the carboxyl terminus of the viral
nucleocapsid protein overnight at 4uC. Appropriate goat Alexa
488 anti-mouse secondary antibodies (Invitrogen) were applied,
and nuclei were stained with DAPI. Sections were analyzed using
an Olympus Fluoview (FV1000) laser scanning confocal micro-
scope, and Volocity image analysis software (Improvision) was
used to generate and analyze confocal images. The number of
Tunel-positive and JHMV-positive cells relative to the total
number of cells was determined from three to five randomly
selected fields from three independent experiments.
Immunoblotting
For western analysis differentiated primary oligodendrocyte
enriched cultures were infected with JHMV (MOI 1.0) for one
hour. Cells were washed and treated with or without recombinant
mouse CXCL1 (Peprotech, NJ) for 24 hours. Cultures were lysed
in RIPA buffer (50 mM TrisHCl pH 7.4, 175 mM NaCl, 5 mM
EDTA, 1% NP-40, 0.1% SDS, 0.5% DOC) supplemented with
protease and phosphatase inhibitors (Roche). Protein extracts
(50 ug) were separated on 12% SDS/PAGE, transferred to PVDF
membranes and blocked at room temperature with PBS 0.05%
Tween-20 plus 5% non-fat milk, then incubated with primary
antibodies overnight at 4uC: rabbit anti – total caspase 3 (1:1000),
rabbit anti – cleaved caspase 3 (1:1,000), rabbit anti – PARP
(1:1,000; Cell Signaling, MA), goat anti – Bcl-2 (1:5,000; R&D
System, MN), and mouse monoclonal actin (1:50,000; Millipore,
MA). Immune complexes were detected using appropriate
peroxidase-conjugated secondary antibodies (1:25,000; Jackson
Immuno) and then exposed to a chemiluminescent reagent
(SuperSignal West-Pico, Pierce). Densitometric analysis was
performed within the linear range with Image J (NIH) and
normalized to actin levels.Results were normalized to respective
control conditions.
Statistical analysis
All data is presented as average 6 SEM. Statistically significant
differences were assessed by one way ANOVA, and p values less
than 0.05 were considered significant.
Supporting Information
Table S1 Frequency of inflammatory cell accumulation within
the CNS is not altered following CXCR2 neutralization.
Found at: doi:10.1371/journal.pone.0011340.s001 (0.03 MB
DOC)
Figure S1 CXCR2 neutralization does not affect Chemokine
mRNA expression. Chemokine mRNA expression within the
brains of anti-CXCR2 or NRS treated JHMV and sham infected
mice was assessed at days 15 and 21 p.i. via ribonuclease
protection assay (A). Each lane indicates an individual mouse.
Quantification of band intensities (B) reveals no significant
differences in chemokine mRNA expression between anti-CXCR2
and NRS treated mice.
Found at: doi:10.1371/journal.pone.0011340.s002 (0.70 MB
TIF)
Figure S2 Oligodendrocytes derived from neural precursor cells
express CXCR2 in vitro. Neural precursor differentiation produced
enriched cultures of Gal/C+ oligodendrocytes, compared to
GFAP+ astrocytes or MAP2+ neurons (A). Immunostaining of
the differentiated oligodendrocytes revealed CXCR2 expression in
vitro (B). Data in panel A is a summation of two independent
experiments. Representative image is shown in panel B.
Found at: doi:10.1371/journal.pone.0011340.s003 (0.89 MB
TIF)
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